In addition, since SCD over-expression has been associated with tumor progression and early-stage CC patient relapse[11, 16], we investigated whether rs522951 polymorphism correlated with gene expression levels of SCD in a subsample of 209 stage II/III CC patients (140 and 69 stage II and III respectively) in which gene expression data was available due to enough amount of sample for DNA and RNA extraction, and gene expression levels had been previously determined [11]. The gene discussed is SCD; the disease is neoplasm.